Front. Immunol. Frontiers in Immunology Front. Immunol. 1664-3224 Frontiers Media S.A. 10.3389/fimmu.2023.1346845 Immunology Correction Corrigendum: Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study Wu Wen-Jie 1 2 3 Liu Qian 1 2 3 An Pu-Gen 1 2 3 Wang Lin 1 2 3 Zhang Jian-Yun 2 3 4 Chen Yan 2 3 4 Zhang Tong 5 Zhang Jie 1 2 3 * 1 Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China 2 National Center of Stomatology & National Clinical Research Center for Oral Diseases, Beijing, China 3 Central Laboratory, Peking University School and Hospital of Stomatology, Beijing, China 4 Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China 5 Departmet of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

Edited and Reviewed by: D. P. Kreil, University of Natural Resources and Life Sciences, Vienna, Austria

*Correspondence: Jie Zhang, zhangjie123@bjmu.edu.cn

05 01 2024 2023 14 1346845 30 11 2023 18 12 2023 Copyright © 2024 Wu, Liu, An, Wang, Zhang, Chen, Zhang and Zhang 2024 Wu, Liu, An, Wang, Zhang, Chen, Zhang and Zhang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a real−world retrospective study by Wu W-J, Liu Q, An P-G, Wang L, Zhang J-Y, Chen Y, Zhang T and Zhang J (2023) Front. Immunol. 14:1282629. doi: 10.3389/fimmu.2023.1282629 neoadjuvant immunotherapy chemotherapy head and neck squamous cell carcinoma section-in-acceptance Cancer Immunity and Immunotherapy

Text Correction

In the published article, there was an error. Some of the statements in the article about the results in Figure 2A were inappropriate.

A correction has been made to Results, Efficacy of neoadjuvant therapy, Line 3-9, Paragraph 2, Page 3. This sentence previously stated:

“A significant difference was observed in the median OS in the MPR (20 months) and non-MPR groups (16 months) respectively (p = 0.0138). In addition, the median DFS showed significant difference and in the MPR (18.5 months) and non-MPR groups (12 months), respectively, (p < .001) (Figure 2A).”

The corrected sentence appears below:

“A significant difference was observed in the OS between the MPR and non-MPR groups (p = 0.0138). In addition, the DFS showed a significant difference between the MPR and non-MPR groups (p < .001) (Figure 2A).”

In the published article, there was an error. Some of the statements in the article about the results in Figure 4B were inappropriate.

A correction has been made to Results, Survival, Line 4-9, Page 5. This sentence previously stated:

“Prognostic evaluation based on the PD-L1 CPS status revealed median OS durations of 22, 19, and 19 months for patients with PD-L1 CPS < 1, 1≤PD-L1 CPS <20, and PD-L1 CPS≥20, respectively (p = .3825). Median DFS durations for the three groups were consistently 16 months (p = .0244) (Figure 4B).”

The corrected sentence appears below:

“Prognostic evaluation based on the PD-L1 CPS status revealed that there was no significant difference in the OS among patients with PD-L1 CPS < 1, 1≤PD-L1 CPS <20, and PD-L1 CPS≥20 (p = .3825). But there was a significant difference in the DFS among the three groups (p = .0244) (Figure 4B).”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.